Joseph Weigel
Psychiatric/Mental Health · Culver City, CANPI 1063563542
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 725 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 725 payments — averaging $25.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- Otsuka America Pharmaceutical, Inc.$2K
- Alkermes, Inc.$2K
- Johnson & Johnson$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Vanda Pharmaceuticals Inc.$2K
- plus $5K from 12 others
What the payments were for
- Food & beverage$18,01598%
- Education$3542%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 134 | $3,140 |
| Otsuka America Pharmaceutical, Inc. | 97 | $2,312 |
| Alkermes, Inc. | 86 | $2,292 |
| Johnson & Johnson | 67 | $2,136 |
| Teva Pharmaceuticals USA, Inc. | 90 | $2,023 |
| Vanda Pharmaceuticals Inc. | 45 | $1,657 |
| E.r. Squibb & Sons, L.L.C. | 34 | $1,335 |
| Neurocrine Biosciences, Inc. | 49 | $1,333 |
| AbbVie | 50 | $708 |
| Lundbeck LLC | 23 | $356 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $261 |
| Sunovion Pharmaceuticals Inc. | 21 | $237 |
| Indivior Inc. | 11 | $236 |
| Bausch Health US, LLC | 7 | $142 |
| Axsome Therapeutics, Inc. | 3 | $90 |
| Eisai Inc. | 3 | $48 |
| Neuronetics, Inc. | 1 | $37 |
| Almatica Pharma LLC | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$2,336
- CAPLYTA$827
- COBENFY$510
- REXULTI$474
- ARISTADA$442
- INVEGA SUSTENNA$389
- SPRAVATO$351
- Fanapt$250
- ABILIFY ASIMTUFII$243
- ABILIFY MAINTENA$237
- INGREZZA$233
- INVEGA TRINZA$125
- ARISTADA INITIO$111
How this compares
$18,369 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 37 | $103,885 |
| CaplytaLumateperone Tosylate | 48 | $85,196 |
| Invega SustennaPaliperidone Palmitate | 28 | $82,148 |
| RexultiBrexpiprazole | 28 | $41,594 |
| VraylarCariprazine Hcl | 28 | $38,247 |
| UzedyRisperidone | 11 | $36,131 |
| ZyprexaOlanzapine | 14 | $20,043 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $18,633 |
| Aripiprazole | 151 | $11,998 |
| Divalproex Sodium ErDivalproex Sodium | 93 | $6,926 |
| Bupropion XlBupropion Hcl | 232 | $3,327 |
| Quetiapine Fumarate | 184 | $3,028 |
| Hydroxyzine Hcl | 73 | $1,464 |
| Olanzapine | 57 | $1,413 |
| Gabapentin | 105 | $1,233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $2,312 | $145,47965 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $3,140 | $85,19648 claims |
| Johnson & JohnsonInvega Sustenna | $2,136 | $82,14828 claims |
| AbbVieVraylar | $708 | $38,24728 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $2,023 | $36,13111 claims |
| Alkermes, Inc.Lybalvi | $2,292 | $18,63312 claims |
| Almatica Pharma LLCSertraline Hcl | $24 | $39998 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Culver City
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- Samantha PerkinsAnaheim$49K
- Yvette ElpidioOrange$43K
- Sarah KoLos Angeles$34K
- Jonathan LlamasPasadena$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.